The effect of Sulforaphane on the treatment of mild to moderate depression in post percutaneous coronary intervention patients

Sulforaphane as a treatment for mild to moderate depression in post percutaneous coronary intervention patients: A randomized double blind and placebo controlled clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090117001556N128

Enrollment

Registered

2020-05-19

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression. Major depressive disorder, single episode, moderate

Interventions

Intervention 1: Intervention group: Sulforaphane tablet (ACECR, Tehran), 30 mg per day for 6 weeks. Intervention 2: Control group: Placebo, once a day for 6 weeks.

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Based on DSM-5 diagnostic criteria, have minor depression disorder Based on Hamilton depression scale, get the score of 14 to 17 Age between 40 to 65 years History of percutaneous coronary intervention

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Presence of other psychiatric disorders Be psychotic History of Electroconvulsive therapy, two months prior to the trial Using psychotropic drug Drug addiction Presence of Thyroid disease

Design outcomes

Primary

Measure	Time frame
Severity of depression. Timepoint: Baseline and weeks 2, 4, and 6. Method of measurement: By Hamilton depression scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026